Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100044/S060

Propel Family Products

Intersect Ent. · Decision date Sep 23, 2026

MEDTECHLEDGER EXPLANATIONP100044/S060

What did the FDA approve?

The FDA recorded an approval dated 2026-09-23 for supplement P100044/S060, submitted by Intersect Ent. under the Propel Family Products. The supplement's stated purpose is a shelf-life extension from 24 months to 36 months, filed as a real-time process supplement with the reason given as a labeling change covering indications, instructions, shelf life or tradename. The product category listed is a drug-eluting sinus stent in the ear, nose and throat specialty, product code OWO.

That approval modifies the terms of the existing P100044 PMA; it is not a new approval of the whole system. The database does not state what evidence supported the extension, what the stent's original indications were, or what labeling text changed, so those details remain unknown. The source statement reports a purpose set by the applicant, which does not by itself establish safety or clinical effectiveness.

FDA approval order statement

Approval for a shelf-life extension of the Propel Family Products from 24 months to 36 months
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Ear, Nose, Throat
Decision date
Sep 23, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P100044/S060
Regulatory pathway
PMA supplement
Product code
OWO
Decision code
APPR
Decision date
Sep 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-eluting sinus stent.

Product code
OWO
FDA device class
3

For the original device and its historical approval scope, see PMA P100044. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P100044/S060 received

    Application receipt date recorded by FDA.

  2. P100044/S060 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P100044. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100044

Product / regulatory recordCompanyPathwayDecision dateSource
PROPELP100044
Intersect Ent.PMA approvalAug 11, 2011FDA
PROPELP100044/S061
Intersect Ent.PMA supplementSep 22, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Intersect Ent.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1555 Adams Dr., Menlo Park, CA, 94025

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records